Solving the world's most pressing challenges
Battelle is a major force in science and technology discovery and in the translation of knowledge into innovative solutions.
Battelle makes the world safer, healthier and more productive.
Battelle's Massively Parallel Sequencing (MPS) capabilities (also known as Next Generation Sequencing) enable more precise identification and characterization of humans, microbes, plants and animals.
Moving MPS to the Mainstream
Massively Parallel Sequencing (MPS) technology has been previously used primarily in research environments, but a growing number of DNA forensic labs are in the process of validating the technology. In this white paper, Battelle offers an implementation roadmap for MPS in forensic labs.
NIJ Study on MPS Webinar
The National Institute of Justice awarded Battelle a 19-month applied research project to evaluate the feasibility of Massively Parallel Sequencing (MPS) technology for forensic science applications. This webinar discusses the results of the study and provides an objective assessment of MPS technologies.
ExactID ushers in the new era of investigative genetics. Our proprietary ExactID software allows you to exploit the full power of Massively Parallel Sequencing (MPS) technologies to find new leads in genetic data that was previously considered unusable.
Identifying drug resistance of microbial pathogens is critical to productive analysis of infectious disease in biosurveillance applications. Battelle’s proprietary software, CRITERIOME, analyzes genomic sequence data to rapidly and accurately identify microbes and to predict potential drug susceptibility/resistance profiles.
STAY CONNECTED WITH BATTELLE